由矩阵金属蛋白酶-2进行的 ATPase (SERCA) 蛋白质分解有助于早期高血压中血管功能障碍
Marcela M Blascke de Mello1, Viviano Gomes de Oliveira Neves1, Juliana Montenegro Parente1
1Department of Pharmacology, Ribeirao Preto Medical School, Brazil.
European journal of pharmacology
|September 6, 2024
概括
多西环素降低了高血压大鼠的矩阵金属蛋白酶-2活性,防止了质网膜 ATPase蛋白解,改善了血管功能.
科学领域:
- 心血管生物学 心血管生物学
- 血管生理学 血管生理学
- 高血压研究 高血压研究
背景情况:
- 高血压会提高矩阵金属蛋白酶-2 (MMP-2) 的活性,导致血管功能障碍.
- 在高血压中,sarcoplasmic网膜 ATPase (SERCA) 的活性降低,从而损害了血管光滑肌功能.
- MMP-2可以蛋白质化SERCA,加剧心脏和血管功能障碍.
研究的目的:
- 调查早期高血压中MMP-2活性升高是否有助于大动脉中SERCA蛋白解.
- 为了确定抑制MMP-2活性是否能改善高血压引起的血管改造和功能障碍.
主要方法:
- 雄性斯普拉格-道利大鼠接受了两次脏一剪切 (2K-1C) 手术或假手术,并接受了多西环林治疗.
- 系统血压 (SBP) 被监测;大动脉被分析MMP-2活性,SERCA水平和ATPase活性.
- 评估了血管反应,细胞增殖 (Ki-67) 和大动脉结构.
主要成果:
- 2K-1C大鼠的SBP升高,大动脉MMP-2活性增加,以及SERCA蛋白解.
- 多西环林治疗降低了MMP-2活性,并防止了SERCA蛋白质分解,而不改变SBP.
- 高血压的大动脉显示横截面积增加,介质与光线比和Ki-67,与乙胆的放松受损;多西环素改善了这些影响.
结论:
- 在高血压期间,多西环林抑制MMP-2活性可以防止大动脉中SERCA蛋白解.
- 多西环林治疗改善了高血压引起的血管改造,并改善了内皮功能.
- 准MMP-2为管理与高血压相关的血管并发症提供了潜在的治疗策略.
相关概念视频
Role of Matrix Metalloproteases in Degradation of ECM
2.3K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
2.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
510
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
510
Hypertension and Regulation of Blood Pressure
2.0K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
Antihypertensive Drugs: Direct Renin Inhibitors
511
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
511
Antihypertensive Drugs: Angiotensin II Receptor Blockers
614
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
614


